Astellas Pharma ((ALPMF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Astellas Pharma is conducting a study titled ‘Japan Post-Marketing Surveillance – Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis.’ The study aims to evaluate the safety and effectiveness of peficitinib in patients with rheumatoid arthritis (RA) in real-world clinical settings. This research is significant as it provides insights into the drug’s performance outside of controlled clinical trials.
The intervention being tested is peficitinib, an oral medication administered once daily after meals. It is designed to treat rheumatoid arthritis by targeting specific pathways involved in the disease process.
This observational study follows a cohort model with a prospective time perspective. The primary focus is to observe and gather data on the drug’s impact in a real-world setting, without any specific allocation or masking involved.
The study began on May 30, 2019, and is currently recruiting participants. The last update was submitted on October 9, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.
The update on this study could influence Astellas Pharma’s stock performance by potentially boosting investor confidence if the results are positive. It also positions the company competitively within the pharmaceutical industry, particularly in the RA treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.